| Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research AD Sherry, KL Corrigan, R Kouzy, JA Jaoude, Y Yang, RR Patel, ... Cancer 129 (21), 3430-3438, 2023 | 4 | 2023 |
| Text Classification of Cancer Clinical Trial Eligibility Criteria Y Yang, S Jayaraj, E Ludmir, K Roberts AMIA Annual Symposium Proceedings 2023, 1304, 2023 | 1 | 2023 |
| Exploring the Generalization of Cancer Clinical Trial Eligibility Classifiers Across Diseases Y Yang, A Gilliam, EB Ludmir, K Roberts arXiv preprint arXiv:2403.17135, 2024 | | 2024 |
| Association of differential censoring with survival and suboptimal control arms among oncology clinical trials EJ Hsu, TA Lin, DR Dabush, Z McCaw, A Koong, C Lin, J Abi Jaoude, ... JNCI: Journal of the National Cancer Institute, djae028, 2024 | | 2024 |
| Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy AD Sherry, P Msaouel, ZR McCaw, J Abi Jaoude, EJ Hsu, R Kouzy, ... European Journal of Cancer 194, 113357, 2023 | | 2023 |
| Causal Models, Prediction, and Extrapolation in Cell Line Perturbation Experiments JP Long, Y Yang, KA Do arXiv preprint arXiv:2207.09991, 2022 | | 2022 |
Ethan LudmirRadiation Oncology, The University of Texas MD Anderson Cancer Center確認したメール アドレス: mdanderson.org
